Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.

2.

Advanced breast cancer patients living longer thanks to improvements in treatment and care

3.

Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.

4.

Induction Immunotherapy Has Durable Survival Benefit in LACC

5.

Cognitive Bias Modification App Fosters Alcohol Avoidance


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot